10-Q quarterly report · filed Nov 5, 2026

ACADIA PHARMACEUTICALS INC (ACAD) Q3 2026 10-Q Quarterly Report

Short answer

ACADIA PHARMACEUTICALS INC (ACAD) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $342M (up 22.8% year over year) with net income of $54M.

Q3 2026 key financials · XBRL

Revenue
$342M
+22.8% YoY · +11.1% QoQ
Net income
$54M
−25.4% YoY · +69.9% QoQ
Operating margin
21.0%
EPS (diluted)
$0.31
−26.2% YoY · +72.2% QoQ

Source: XBRL data from the ACADIA PHARMACEUTICALS INC (ACAD) Q3 2026 10-Q on SEC EDGAR. USD.

ACADIA PHARMACEUTICALS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $342.3M, up $63.7M YoY from $278.6M
  • DAYBUE products best performer, $140.1M vs $101.1M, up $39.0M YoY
  • Gross margin approximately 90% vs 92% YoY, pressured by higher DAYBUE sales mix
  • Cash and investments $976.4M vs $819.7M at December 31, 2025, operating cash flow $146.3M
  • Outlook: cash sufficient through and beyond next 12 months, $35.0M Neuren milestone due after first EU DAYBU sale

Risk Factors

  • Newly added tariff risk triggered by U.S. pharmaceutical trade investigations, potentially raising costs and delaying supply-chain adjustments
  • Most materially updated supply risk: DAYBUE API production requires approximately twelve months, increasing vulnerability to disruptions
  • Regulatory risk: EU HTA Regulation entered application January 12, 2025, creating uncertain evidence requirements and reimbursement timing
  • Clinical risk: RADIANT Phase 2 narrowly missed its primary endpoint, prompting removal of the 30 mg remlifanserin dosage arm
  • Liquidity risk: cash, cash equivalents, investment securities and anticipated product sales expected to fund operations through and beyond the next 12 months

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ACADIA PHARMACEUTICALS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.